Facility design and manufacturing processes are complex, multi-stage operations, fraught with difficulty. Ensuring the facility meets Good Manufacturing Practice (GMP) standards and other regulatory requirements is a major challenge. The complex regulations around biomanufacturing facilities require careful planning and documentation from the earliest design stages.
Which is why consensus standards like ASTM E2500 exist.

Central to these approaches are risk assessment, to which there are three primary components:
- An understanding of the uncertainties in the design (which includes materials, processing, equipment, personnel, environment, detection systems, feedback control)
- An identification of the hazards and failure mechanisms
- An estimation of the risks associated with each hazard and failure
Folks often get tied up on what tool to use. Frankly, this is a phase approach. We start with a PHA for design, an FMEA for verification and a HACCP/Layers of Control Analysis for Acceptance. Throughout we use a bow-tie for communication.
| Aspect | Bow-Tie | PHA (Preliminary Hazard Analysis) | FMEA (Failure Mode and Effects Analysis) | HACCP (Hazard Analysis and Critical Control Points) |
|---|---|---|---|---|
| Primary Focus | Visualizing risk pathways | Early hazard identification | Potential failure modes | Systematically identify, evaluate, and control hazards that could compromise product safety |
| Timing in Process | Any stage | Early development | Any stage, often design | Throughout production |
| Approach | Combines causes and consequences | Top-down | Bottom-up | Systematic prevention |
| Complexity | Moderate | Low to moderate | High | Moderate |
| Visual Representation | Central event with causes and consequences | Tabular format | Tabular format | Flow diagram with CCPs |
| Risk Quantification | Can include, not required | Basic risk estimation | Risk Priority Number (RPN) | Not typically quantified |
| Regulatory Alignment | Less common in pharma | Aligns with ISO 14971 | Widely accepted in pharma | Less common in pharma |
| Critical Points | Identifies barriers | Does not specify | Identifies critical failure modes | Identifies Critical Control Points (CCPs) |
| Scope | Specific hazardous event | System-level hazards | Component or process-level failures | Process-specific hazards |
| Team Requirements | Cross-functional | Less detailed knowledge needed | Detailed system knowledge | Food safety expertise |
| Ongoing Management | Can be used for monitoring | Often updated periodically | Regularly updated | Continuous monitoring of CCPs |
| Output | Visual risk scenario | List of hazards and initial risk levels | Prioritized list of failure modes | HACCP plan with CCPs |
| Typical Use in Pharma | Risk communication | Early risk identification | Detailed risk analysis | Product Safety/Contamination Control |
At BOSCON this year I’ll be talking about this fascinating detail, perhaps too much detail.

One thought on “Risk Assessments as part of Design and Verification”